ReviewFrontiers in immunology2020
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 150 citations in OpenAlex.
- First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.Clinical and translational science · 2023Trial
- Trial
- Cold agglutination as a pivotal diagnostic clue for Waldenström macroglobulinemia: A rare case report with diagnostic and therapeutic insights.Experimental and therapeutic medicine · 2026Article
- Post-EBV Cold Urticaria with High-Titre Cold Agglutinins without Haemolysis: A Paediatric Case Report.Mediterranean journal of rheumatology · 2026Article
- Revealing and quantifying polyclonal anti-A, B specificity in ABO histo-blood groups.Transfusion · 2026Article
- Occurrence of Cold Agglutinin Disease among Patients with Autoimmune Hemolytic Anemia: A Hungarian Single-Center Experience.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- Sutimlimab in Patients With Cold Agglutinin Disease (CAD): Results From a Managed Access Program.European journal of haematology · 2026Article
- Host immune dysfunction and Mycoplasma pneumoniae immune evasion: dual drivers of pathogenesis in Mycoplasma pneumoniae pneumonia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Nomogram to predict severeFrontiers in pediatrics · 2026Article
- Article
- Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report.Frontiers in immunology · 2026Article
- A Rare Case of Severe Cold Autoimmune Hemolytic Anemia in a Hemochromatosis Carrier.Case reports in hematology · 2026Article
- Article
- [Cold agglutinin disease (CAD)].Innere Medizin (Heidelberg, Germany) · 2025Review
- Successful treatment of refractory cold agglutinin syndrome using fixed-duration daratumumab, bortezomib and dexamethasone with a sutimlimab bridge.Haematologica · 2025Article
- Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses.Clinical pharmacology and therapeutics · 2025Article
- Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.EJHaem · 2025Article
- Reactive Infectious Mucocutaneous Eruption (RIME): Narrative Review and Proposed Management Algorithm.Dermatology practical & conceptual · 2025Review
- Cryoproteins in Non-HCV-Related Autoimmune Disorders: A Serious Cold-Induced Problem.Diagnostics (Basel, Switzerland) · 2025Review
- From Yellow Cumulus to Pregnancy in Autoimmune Hemolytic Anemia Following Bilirubin Reduction: A Case Report.Cureus · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemias mediated by cold agglutinins can be divided into cold agglutinin disease (CAD), which is a well-defined clinicopathologic entity and a clonal lymphoproliferative disorder, and secondary cold agglutinin syndrome (CAS), in which a similar picture of cold-hemolytic anemia occurs secondary to another distinct clinical disease. Thus, the pathogenesis in CAD is quite different from that of polyclonal autoimmune diseases such as warm-antibody AIHA. In both CAD and CAS, hemolysis is mediated by the classical complement pathway and therefore can result in generation of anaphylotoxins, such as complement split product 3a (C3a) and, to some extent, C5a. On the other hand, infection and inflammation can act as triggers and drivers of hemolysis, exemplified by exacerbation of CAD in situations with acute phase reaction and the role of specific infections (particularly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.